Business Wire

CA-ASM-GLOBAL

17.4.2024 15:01:29 CEST | Business Wire | Press release

Share
Kai Tak Sports Park Limited and ASM Global Begin Countdown to Unveiling of World’s Largest Sports Development in History

The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire)

ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of 2025’s formal unveiling.

The project will include a 50,000-capacity main stadium with the theme “Pearl of the Orient” as its design inspiration and boasting a retractable roof and flexible pitch surface that can host a wide range of events in any weather, including major sports events, concerts and MICE events; a 10,000-capacity indoor sports arena that meets the standard of major international tournaments for a wide range of athletics, including basketball, tennis, gymnastics, family shows and other entertainment events; a 5,000-spectator, open-to-the-public sports ground for hosting school sports days, athletic meets, local football and rugby matches as well as team and athlete training sessions; and an outdoor recreation complex.

ASM Global’s President and CEO Ron Bension said, “ASM Global develops and builds spectacular venues and extraordinary entertainment districts throughout the world; but nothing compares to the scale, scope and state-of-the art innovation of Kai Tak.”

The Hong Kong site is part of ASM Global’s network of more than 400 venues around the world. The company works with major cultural and entertainment districts and venues and projects throughout the world, including Darling Harbour in Sydney, OVO Arena Wembley in London, AO Arena in Manchester and Desert Diamond in Arizona.

Officials said the expansive development will set the benchmark for multipurpose sports precincts worldwide, integrating the most advanced sports facilities with retail, wellness and community leisure spaces to create an urban oasis for the 7.4 million local community and millions of overseas visitors.

KTSPL, when awarded the contract for the design, build, construction and operation of the Kai Tak Sports Park, subsequently assembled an unparalleled project team comprising overseas and local experts in design; retail sales and marketing; construction led by Hip Hing; and ASM Global for project management, premium sales and programming.

The precinct is designed around the one-of-a-kind Kai Tak Sports Avenue. This indoor and outdoor pedestrian walk starts at Station Square and transports people completely through the immense site.

Throughout the complex will be restaurants, retail shops, jogging trails, a health and wellness center, as well as an international-standard bowling center with 40 lanes suitable for hosting international tournaments and a climbing wall on Sports Avenue.

ASM Global and KTSPL’s state-of-the-art environmentally conscious design decisions are critical to the project, intended to set and meet measurable goals to reduce impacts on the planet and champion dynamic programs for the longevity and well-being of the local community.

The focus of these sustainability efforts includes integration of photovoltaic panels on all major facilities, extensive green roofscapes and an expansive network of electric charging stations across the precinct. Smart city initiatives include an intelligent building and car management system, Wi-Fi hotspots, an indoor positioning system and mobile applications to facilitate precinct information booking of facilities and wayfinding.

Kai Tak Sports Park is expected to formally open in early 2025 and is one of the sports venues that will deliver events for the 2025 15th National Games of China that is being hosted in the Greater Bay Area.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417546819/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye